BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 26341752)

  • 1. Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study.
    Tvedskov TF; Jensen MB; Ejlertsen B; Christiansen P; Balslev E; Kroman N
    Breast Cancer Res Treat; 2015 Oct; 153(3):599-606. PubMed ID: 26341752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staging of women with breast cancer after introduction of sentinel node guided axillary dissection.
    Tvedskov TF
    Dan Med J; 2012 Jul; 59(7):B4475. PubMed ID: 22759850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evolution of the sentinel node procedure in the treatment of breast cancer.
    Tvedskov TF
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel node.
    Tvedskov TF; Jensen MB; Lisse IM; Ejlertsen B; Balslev E; Kroman N
    Int J Cancer; 2012 Nov; 131(10):2367-75. PubMed ID: 22344558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumour cells or micrometastases in sentinel nodes.
    Houvenaeghel G; Boher JM; Reyal F; Cohen M; Garbay JR; Classe JM; Rouzier R; Giard S; Faure C; Charitansky H; Tunon de Lara C; Daraï E; Hudry D; Azuar P; Gimbergues P; Villet R; Sfumato P; Lambaudie E
    Eur J Cancer; 2016 Nov; 67():106-118. PubMed ID: 27640137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Sentinel Node with Isolated Breast Tumor Cells or Micrometastases. Benefits and Risks of Axillary Dissection.
    Madekivi V; Boström P; Aaltonen R; Vahlberg T; Salminen E
    Anticancer Res; 2017 Jul; 37(7):3757-3762. PubMed ID: 28668871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes.
    Andersson Y; Bergkvist L; Frisell J; de Boniface J
    Breast Cancer Res Treat; 2018 Sep; 171(2):359-369. PubMed ID: 29846847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes.
    Bonneau C; Hequet D; Estevez JP; Pouget N; Rouzier R
    Eur J Surg Oncol; 2015 Aug; 41(8):998-1004. PubMed ID: 25986854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival impact and predictive factors of axillary recurrence after sentinel biopsy.
    Houvenaeghel G; Classe JM; Garbay JR; Giard S; Cohen M; Faure C; Charytansky H; Rouzier R; Daraï E; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Fraisse J; Dravet F; Chauvet MP; Goncalves A; Lambaudie E
    Eur J Cancer; 2016 May; 58():73-82. PubMed ID: 26971077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Completion axillary dissection can safely be omitted in screen detected breast cancer patients with micrometastases. A decade's experience from a single institution.
    Grabau D; Dihge L; Fernö M; Ingvar C; Rydén L
    Eur J Surg Oncol; 2013 Jun; 39(6):601-7. PubMed ID: 23579175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.
    Pernas S; Gil M; Benítez A; Bajen MT; Climent F; Pla MJ; Benito E; Guma A; Gutierrez C; Pisa A; Urruticoechea A; Pérez J; Gil Gil M
    Ann Surg Oncol; 2010 Mar; 17(3):772-7. PubMed ID: 20183912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axillary and systemic treatment of patients with breast cancer and micrometastatic disease or isolated tumor cells in the sentinel lymph node.
    Maaskant-Braat AJ; Voogd AC; van de Poll-Franse LV; Coebergh JW; Nieuwenhuijzen GA
    Breast; 2012 Aug; 21(4):524-8. PubMed ID: 22516371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study.
    Reed J; Rosman M; Verbanac KM; Mannie A; Cheng Z; Tafra L
    J Am Coll Surg; 2009 Mar; 208(3):333-40. PubMed ID: 19317993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival after negative sentinel lymph node biopsy in breast cancer at least equivalent to after negative extensive axillary dissection.
    Kuijt GP; van de Poll-Franse LV; Voogd AC; Nieuwenhuijzen GA; Roumen RM
    Eur J Surg Oncol; 2007 Sep; 33(7):832-7. PubMed ID: 17197151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node biopsy alone has no adverse impact on the survival of patients with breast cancer.
    Takei H; Suemasu K; Kurosumi M; Horii Y; Ninomiya J; Yoshida M; Hagiwara Y; Inoue K; Tabei T
    Breast J; 2006; 12(5 Suppl 2):S157-64. PubMed ID: 16958996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes.
    van Rijk MC; Peterse JL; Nieweg OE; Oldenburg HS; Rutgers EJ; Kroon BB
    Cancer; 2006 Aug; 107(3):467-71. PubMed ID: 16804924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-validation of three predictive tools for non-sentinel node metastases in breast cancer patients with micrometastases or isolated tumor cells in the sentinel node.
    Tvedskov TF; Meretoja TJ; Jensen MB; Leidenius M; Kroman N
    Eur J Surg Oncol; 2014 Apr; 40(4):435-41. PubMed ID: 24534362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells.
    Pepels MJ; de Boer M; Bult P; van Dijck JA; van Deurzen CH; Menke-Pluymers MB; van Diest PJ; Borm GF; Tjan-Heijnen VC
    Ann Surg; 2012 Jan; 255(1):116-21. PubMed ID: 22183034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.
    Langer I; Guller U; Viehl CT; Moch H; Wight E; Harder F; Oertli D; Zuber M
    Ann Surg Oncol; 2009 Dec; 16(12):3366-74. PubMed ID: 19760047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.